TECENTRIQ® Education Presentation
Loading Map....
On behalf of Genentech, you are invited to attend an expert-led education presentation:
TECENTRIQ®: The First FDA-Approved Anti-PDL1 Cancer Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma (mUC)